N/A N=37 Biobehavioral Pathways Underlying Alcohol Use and Health
Alcohol Use Disorder · Liver Diseases
Primary: Percentage of Screen Eligible Who Enroll — 28; 5 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=75 Aripiprazole for Bipolar Disorder and Alcohol Use Disorder
Bipolar Disorder · Alcoholism · Alcohol Abuse
Primary: Timeline Follow Back (TLFB) — -0.82; -0.71 drinks per drinking day
N/A N=134 Records for Alcohol Care Enhancement
Alcohol Use Disorder (AUD)
Primary: Percent of New Alcohol Use Disorder (AUD) Diagnosis Episodes That Meet Criteria for AUD Treatment Engagement Among Patients With a New AUD Diagnosis Who Are Empaneled to…
Phase 2 N=60 Human Laboratory Study of ASP8062 for Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Drinking · Alcohol Use Disorder (AUD)
Primary: Alcohol Craving — 6.44; 6.26 score on a scale — p=0.784
Phase 2 N=48 Semaglutide for Alcohol Use Disorder
Alcohol Use Disorder · Cigarette Smoking
Primary: Change in Alcohol Consumed — -32.72; -6.95 grams
N/A N=60 Acute Alcohol Response In Bipolar Disorder: a fMRI Study
Bipolar Disorder · Alcohol Drinking · Alcohol Use Disorder
Primary: Level of Intoxication (Subjective Response) on Each Condition Day After Drinking Relative to How They Felt When Arriving to the Lab on That Respective Day )Prior to…
Phase 2 N=27 Effects of Cannabidiol in Alcohol Use Disorder
Alcohol Use Disorder
Primary: Trough CBD Plasma Levels — 0; 0.7 CBD (ng/mL)
N/A N=2 Deep Brain Stimulation for Alcohol Use Disorder
Alcohol Use Disorder
Primary: Number of Serious Adverse Events (Safety and Tolerability) — 1; 1 Adverse Events
Early Phase 1 N=44 Inpatient Single Dose Interventions for Alcohol Use Disorder
Alcohol Use Disorder, Severe
Primary: Rate (%) of 30-day Hospital Re-admission — 3; 2; 7 Participants
Phase 2 N=46 Varenicline to Reduce Alcohol Consumption in Heavy Drinkers
Alcohol Drinking
Primary: Alcohol Consumption — 92.0; 77.3 mg/%
Phase 2 N=150 ABT-436 for Alcohol Dependence
Alcohol Dependence · Alcohol Abuse · Alcohol Use Disorders
Primary: Weekly Percentage of Heaving Drinking Days — 37.6; 31.3 weekly percentage of heavy drinking days
Phase 2 N=200 Varenicline for Alcohol Dependence
Alcoholism
Primary: Weekly Percentage of Heavy Drinking Days — 37.9; 48.4 percentage of heavy drinking days
Phase 2 N=4 Open Label Pilot Study of Perampanel for the Treatment of Alcohol Use Disorder
Alcohol Disorders
Primary: Percent Abstinent Days — 3.13; 100 Percentage of days
Phase 2 N=50 Medication Development for Protracted Abstinence in Alcoholism: CORT118335 Versus Placebo
Alcohol Use Disorder
Primary: Craving to Drink — 31.1; 33.2 score on a scale — p=.065
Phase 1 N=26 Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
Alcohol Dependence
Primary: Craving for Alcohol in Alcohol Dependence With Citalopram Compared to Placebo — 21; 30.4; 10.8; 10.6 score on a scale
N/A N=285,304 Sustaining Patient-centered Alcohol-related Care
Alcohol, Drinking · Alcohol Use Disorder
Primary: Brief Alcohol Counseling Rate — 57; 11 participants per 10,000 with visits — p=<.001
Phase 4 N=41 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder
Alcohol Dependence · Anxiety Disorder
Primary: Treatment Adherence — 15 Participants
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants
N/A N=123 Contingency Management of Alcohol Abuse in the Severely Mentally ILL
Alcohol Abuse · Schizophrenia · Bipolar Disorder
Primary: Alcohol Use as Assessed by Ethyl Glucuronide Detection in Urine — 408.86; 734.79 EtG Value (nanograms per milileter)
N/A N=185 Pioglitazone for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder
Primary: Heavy Drinking Days Per Week Change — -1.76; -2.3 Mean heavy drinking days per week
Phase 2 N=27 Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home
Alcohol-Related Disorders · Alcohol Drinking · Alcoholism
Primary: Weekly Change in Drinking — -11.4; -22.2; -39.6; -29.3 score on a scale
Phase 4 N=248 Alcohol Disorder hOsPital Treatment Trial
Heavy Drinking · Alcohol Dependence · Alcohol Use Disorder
Primary: Change in Percent Heavy Drinking Days (%HDDs) Over the Past 30 Days From Baseline to 3 Month Follow-up, Assessed Using the Timeline Follow-Back — -46.4; -38.4 change in…
Phase 2 N=255 A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder
Schizophrenia · Alcohol Use Disorder
Primary: Number of Participants With Independent Adjudication Committee (IAC) Adjudicated Event of Exacerbation of Disease (EEDS) — 25; 29; 87; 88 Participants — p=0.746
Phase 2 N=12 Modafinil for the Treatment of Alcohol Use Disorders
Alcohol Use Disorder
Primary: Time to Relapse — 16; 43 days
Phase 2 N=69 Combined Treatment for Alcohol-Dependent Individuals With PTSD
Stress Disorders, Post-Traumatic · Alcohol Abuse · Substance-Related Disorders
Primary: Heavy Drinking Days/Week — 3.13; 2.89; 1.05; 0.48 Days/Week — p=0.34
N/A N=3 Pilot Human Laboratory Study of Alcohol Approach Bias Modification (AABM) for Alcohol Use Disorder (AUD)
Alcohol Use Disorder
Primary: Recruitment Feasibility — 3 Participants
Phase 2 N=100 Intranasal Oxytocin for the Treatment of Alcohol Use Disorder
Alcohol Use Disorder · Alcohol Misuse
Primary: Weekly Percentage of Heavy Drinking Days — 51.5; 52.9 percentage of days per week
Phase 2 N=44 Effect of Varenicline on Fixed-Dose Alcohol Administration in Participants With Alcohol Use Disorders
Alcohol Reactivity
Primary: Cognitive Function as Measured by Omissions on the CPT — 1.78; 1.28; 4.76; 0.98 Number of Omissions
N/A N=75 Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders
Alcohol Use Disorder · Anxiety Disorders
Primary: Mean Number of Drinks Consumed Per Week — 40.82; 29.62; 12.12; 23.86 Standard Drinking Units per Week — p=0.002
N/A N=392 Individualizing Incentives for Alcohol in the Severely Mentally Ill
Schizophrenia · Bipolar Disorder · Major Depressive Disorder
Primary: Alcohol Use Assessed by Ethyl Glucuronide (EtG) Detection in Urine — 0.66; 0.65; 0.61 proportion uEtG negative